Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: A study of morbidity and survival Conference

Lambrou, NC, Gómez-Marín, O, Mirhashemi, R et al. (2004). Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: A study of morbidity and survival . 93(3), 653-658. 10.1016/j.ygyno.2004.03.015



cited authors

  • Lambrou, NC; Gómez-Marín, O; Mirhashemi, R; Beach, H; Salom, E; Almeida-Parra, Z; Peñalver, M

fiu authors

abstract

  • Objective. To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction. Method. All patients with endometrial carcinoma who underwent primary surgical therapy at the University of Miami between January 1, 1990 and June 1, 2002 were identified. Patients meeting FIGO criteria for Stage III or IV disease were selected. Papillary serous and clear cell histology was excluded. Results. Eighty-five patients were identified: 66 Stage III and 19 Stage IV. Only Stage IIIC and Stage IV were included in survival analysis: 72% (33 Stage IIIC, 9 Stage IV) had optimal cytoreduction and 28% (6 Stage IIIC, 10 Stage IV) had suboptimal cytoreduction. The median survival for Stage IIIC and IV disease was 6.7 months for patients with suboptimal cytoreduction and 17.8 months for patients with optimal cytoreduction (P = 0.001). The proportion of patients with major postoperative complications (37.50% vs. 7.25%, P = 0.005), unplanned postoperative SICU admissions (31.25% vs. 7.25%, P = 0.018), and length of hospital stay exceeding 15 days (31.25% vs. 4.35%, P = 0.005) was greater in patients with suboptimal cytoreductive surgery. Conclusions. Overall survival is lower and morbidity is higher in patients with advanced endometrial carcinoma having suboptimal cytoreduction at the time of primary surgery. Patients with suspected advanced stage endometrial carcinoma should be counseled on the potential benefits of optimal cytoreductive surgery. Alternative treatment options should be considered in those patients with surgically unresectable disease. © 2004 Elsevier Inc. All rights reserved.

publication date

  • June 1, 2004

Digital Object Identifier (DOI)

start page

  • 653

end page

  • 658

volume

  • 93

issue

  • 3